ArticleMolecular oncology2026
Recurrent cancer-associated ERBB4 mutations are transforming and confer resistance to targeted therapies.
Veera K Ojala et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it